Physician profile
John Cary
NPI 1346709417
$1,164.02
in general payments reported to CMS, 2019-2025
11 companies · $404 in 2025
The $404 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $200 · 2023: $294 · 2024: $110 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.79 | 2021-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $183.97 | 2025 | Opzelura |
| Dermavant Sciences, INC. | $172.57 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $172.10 | 2021-2025 | Dupixent |
| Genzyme Corporation | $98.66 | 2022 | |
| Arcutis Biotherapeutics, INC. | $96.33 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $85.19 | 2022-2023 | Sotyktu |
| Amgen INC. | $46.45 | 2022-2023 | Amjevita |
| Helsinn Therapeutics (U.S.), INC. | $24.88 | 2022 | |
| Pfizer INC. | $24.46 | 2024 | |
| Lnhc, INC | $16.62 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.